CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL EFFECTS OF AMPLIGEN, A MISMATCHED DOUBLE-STRANDED RNA, IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
Document Type
Journal Article
Publication Date
6-6-1987
Journal
The Lancet
Volume
329
Issue
8545
DOI
10.1016/S0140-6736(87)90543-5
Abstract
10 patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), or lymphadenopathy syndrome (LAS) were given 200-250 mg ampligen, a mismatched double-stranded (ds) RNA with in-vitro antiviral activity against human immunodeficiency virus (HIV), twice a week for up to 18 weeks, without side-effects or toxicity. In all 9 patients who were positive for HIV RNA in peripheral blood mononuclear cells before therapy, levels became undetectable between days 10 and 40 of the start of therapy. 6 of the 7 patients with ARC or LAS also showed a progressive reduction in HIV load as measured by co-culture assays. All 10 patients had augmentation of delayed-type hypersensitivity skin reactions. Other changes noted during ampligen therapy included an increase in or maintenance of numbers of helper-inducer T lymphocytes, improvements in HIV-related symptoms, rises in titre of neutralising antibodies against HIV, and restoration of proper functioning of the natural lymphocyte antiviral dsRNA-dependent (2'-5' oligoadenylate/RNA-ase L) pathway. Thus, in the short term, ampligen seems to have the dual ability to restore immunological function and to control HIV replication. © 1987.
APA Citation
Carter, W., Brodsky, I., Pellegrino, M., Henriques, H., Parenti, D., Schulof, R., Robinson, W., Volsky, D., Paxton, H., Karikó, K., Suhadolnik, R., Strayer, D., Lewin, M., Einck, L., Simon, G., Scheib, R., & Montefiori, D. (1987). CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL EFFECTS OF AMPLIGEN, A MISMATCHED DOUBLE-STRANDED RNA, IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX. The Lancet, 329 (8545). http://dx.doi.org/10.1016/S0140-6736(87)90543-5